<DOC>
	<DOCNO>NCT00312013</DOCNO>
	<brief_summary>This study evaluate effect nadroparin survival disease progression patient hormone-refractory prostate cancer ( HRPC ) , locally advanced pancreatic cancer non-small-cell lung carcinoma ( NSCLC ) .</brief_summary>
	<brief_title>Effects Of Nadroparin In Patients With Lung , Pancreas Or Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Nadroparin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Inclusion criterion : Hormone refractory prostate cancer within 6 month diagnosis , OR locally advance ( nonmetastasized ) pancreatic cancer within 3 month diagnosis , OR nonsmallcell lung cancer within 3 month stage IIIB . Exclusion criterion : Life expectancy &lt; 3 month . Poor performance status ( Karnofsky &lt; 60 ) . Need anticoagulant . Use nadroparin ( low molecular weight heparin ) reason include history heparininduced thrombocytopenia . Have brain metastasis . At high risk bleed platelet count &lt; 50,000/mm3 . Have poor kidney function .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>low molecular weight heparin</keyword>
	<keyword>nadroparin</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>cancer survival</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>pancreatic cancer</keyword>
</DOC>